NCT07780669RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 624 (estimated)
- First submitted
- 19 Aug 2026
- Start date
- 27 Aug 2026
- Primary completion date
- 20 Jul 2029
- Lead sponsor
- GlaxoSmithKline
- Diseases
- COPD
- NCT number
- NCT07780669
- EudraCT number
- 2026-526969-17
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 624
- From 27 Aug 2026 to the primary completion date, 20 Jul 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or prior physician diagnosis of asthma
- Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.
- Continuous oxygen therapy (more than 16 hours/ day).
Other illness
- Other clinically significant lung disease.
- Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure.
- Cor pulmonale resulting in right heart failure and severe pulmonary hypertension.
- A current malignancy or history of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix).
- Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia.
- New York Heart Association class III or IV heart failure.
- Other significant medical conditions that could impact participants' safety or study outcomes.
Who the study is looking for
- Male or eligible female participants
- Participants with \>=40 to less than or equal to (\<=) 80 years of age.
- An eosinophilic phenotype with elevated BEC.
- Moderate to very severe COPD with frequent exacerbations.
- Participants with elevated COPD assessment test (CAT) score.
- Current or former cigarette smokers.
- On triple (Inhaled corticosteroid \[ICS\]+ Long-acting muscarinic antagonist \[LAMA\]+ Long-acting beta-agonist \[LABA\]) or dual inhaled COPD therapy, if ICS is considered not appropriate.
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| GSK Investigational Site Coordinator of this site? Confirm its status | Doral | United States | Recruiting |
| GSK Investigational Site Coordinator of this site? Confirm its status | Lake Charles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.